Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TRVN

Trevena Inc

Apr 18 • 04:00PM ET

0.3660

Dollar change -0.0360
Percentage change -8.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	2.41%	Shs Outstand	18.32M	Perf Week	-11.38%
Market Cap	6.71M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	0.00%	Shs Float	17.88M	Perf Month	-33.45%
Income	-40.27M	PEG	-	EPS next Q	-0.47	Inst Own	7.97%	Short Float	0.63%	Perf Quarter	-45.82%
Sales	3.13M	P/S	2.14	EPS this Y	45.57%	Inst Trans	-3.47%	Short Ratio	0.62	Perf Half Y	-39.30%
Book/sh	-0.44	P/B	-	EPS next Y	21.22%	ROA	-90.21%	Short Interest	0.11M	Perf Year	-49.84%
Cash/sh	1.80	P/C	0.20	EPS next 5Y	-	ROE	-1014.13%	52W Range	0.30 - 3.28	Perf YTD	-49.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.28%	ROI	-146.04%	52W High	-88.84%	Beta	1.11
Dividend TTM	-	Quick Ratio	4.66	Sales past 5Y	2058.58%	Gross Margin	22.52%	52W Low	21.96%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	4.66	EPS Y/Y TTM	59.40%	Oper. Margin	-1128.89%	RSI (14)	31.46	Volatility	12.26% 11.31%
Employees	23	Debt/Eq	-	Sales Y/Y TTM	1194.50%	Profit Margin	-1288.26%	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-44.50%	Payout	-	Rel Volume	6.77	Prev Close	0.40
Sales Surprise	-156.45%	EPS Surprise	-178.95%	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	180.91K	Price	0.37
SMA20	-13.37%	SMA50	-28.65%	SMA200	-45.42%	Trades		Volume	1,224,198	Change	-8.96%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-21	Initiated	Oppenheimer	Perform
Sep-14-20	Initiated	Guggenheim	Buy	$5
Aug-28-20	Initiated	Cantor Fitzgerald	Overweight	$5
May-31-19	Resumed	H.C. Wainwright	Buy
Nov-05-18	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-12-18	Downgrade	Needham	Buy → Hold
Oct-10-18	Downgrade	Jefferies	Buy → Hold
Nov-08-17	Reiterated	Needham	Buy	$9 → $7
Oct-16-17	Downgrade	Barclays	Overweight → Equal Weight	$15 → $2.50
Oct-12-17	Reiterated	H.C. Wainwright	Buy	$8 → $7
May-08-17	Reiterated	Needham	Buy	$11 → $9
Feb-23-17	Reiterated	H.C. Wainwright	Buy	$11 → $8
Feb-22-17	Reiterated	FBR & Co.	Outperform	$13 → $8
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$15
Jan-09-17	Initiated	H.C. Wainwright	Buy	$11
Jan-05-17	Initiated	Oppenheimer	Outperform
May-17-16	Reiterated	Needham	Buy	$14 → $11
May-17-16	Reiterated	FBR Capital	Outperform	$13 → $16
Mar-29-16	Initiated	FBR Capital	Outperform	$16
Sep-01-15	Reiterated	Wedbush	Outperform	$15 → $20

Show Previous Ratings

Apr-01-24 07:13AM	Trevena: Q4 Earnings Snapshot (Associated Press Finance) -13.04%
07:00AM	Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Dec-28-23 02:00PM	Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise (GlobeNewswire)
Dec-27-23 09:10AM	Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise (GlobeNewswire)
Dec-04-23 07:02AM	Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting (GlobeNewswire)
07:00AM	Loading…
07:00AM	Trevena Awarded OLINVYK Agreement with Premier, Inc. (GlobeNewswire)
Nov-30-23 07:00AM	Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries (GlobeNewswire)
Nov-15-23 03:08PM	Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 07:35AM	Trevena: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Trevena Reports Third Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Nov-09-23 07:00AM	Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies (GlobeNewswire) +7.14%
Oct-02-23 07:00AM	Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference (GlobeNewswire)
Sep-06-23 07:01AM	Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update (GlobeNewswire) +14.27%
07:00AM	Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement (GlobeNewswire)
07:07AM	Loading…
Aug-14-23 07:07AM	Trevena: Q2 Earnings Snapshot (Associated Press Finance) +5.84%
07:00AM	Trevena Reports Second Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Jul-20-23 07:00AM	Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors (GlobeNewswire)
Jun-26-23 07:00AM	Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study (GlobeNewswire)
May-31-23 07:00AM	Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical (GlobeNewswire)
May-30-23 07:00AM	Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones (GlobeNewswire)
May-15-23 09:01PM	Q1 2023 Trevena Inc Earnings Call (Thomson Reuters StreetEvents) -12.59%
07:17AM	Trevena: Q1 Earnings Snapshot (AP Finance)
07:00AM	Trevena Reports First Quarter 2023 Results and Provides Business Update (GlobeNewswire)
May-11-23 05:25PM	Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.00%
May-09-23 07:00AM	Trevena to Release First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire) -43.09%
May-08-23 07:00AM	Trevena Announces Approval of OLINVYK in China (GlobeNewswire) +393.65%
May-03-23 07:00AM	Trevena to Participate in Three Upcoming Conferences (GlobeNewswire) +7.61%
Apr-09-23 07:34PM	Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 07:02AM	Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study (GlobeNewswire)
07:00AM	Loading…
07:00AM	Trevena Reports Fourth Quarter 2022 Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 (GlobeNewswire) +15.84%
Mar-09-23 10:21AM	Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate (Zacks)
Mar-07-23 07:00AM	Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders (GlobeNewswire)
Feb-14-23 08:00AM	Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY (GlobeNewswire)
Jan-09-23 07:00AM	Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement (GlobeNewswire)
Dec-08-22 07:00AM	Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings (GlobeNewswire)
Nov-29-22 07:00AM	Trevena Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-16-22 08:00AM	Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Nov-09-22 04:01PM	Trevena Announces Reverse Stock Split (GlobeNewswire) -30.74%
08:25AM	Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:02AM	Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator (GlobeNewswire)
07:00AM	Trevena Reports Third Quarter 2022 Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Oct-24-22 07:00AM	Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (GlobeNewswire)
Sep-07-22 07:00AM	Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 12:00PM	What Makes Trevena (TRVN) a New Buy Stock (Zacks)
Aug-12-22 06:48AM	We're A Little Worried About Trevena's (NASDAQ:TRVN) Cash Burn Rate (Simply Wall St.) +5.34%
Aug-11-22 08:25AM	Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Trevena Reports Second Quarter 2022 Results and Provides Business Update (GlobeNewswire)
Aug-08-22 07:00AM	Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 (GlobeNewswire)
Jul-29-22 05:27PM	Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock (GlobeNewswire) -5.67%
08:00AM	Trevena, Inc. Announces Registered Direct Offering of Preferred Stock (GlobeNewswire)
Jul-28-22 09:41AM	Trevena's Pain Management Drug Shows Better Cognitive Function Than Morphine (Benzinga)
07:00AM	Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update (GlobeNewswire)
Jun-14-22 07:00AM	Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care (GlobeNewswire)
Jun-10-22 07:00AM	Trevena to Participate at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-18-22 04:05PM	Trevena to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-11-22 08:15AM	Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -31.82%
07:00AM	Trevena Reports First Quarter 2022 Results and Provides Business Update (GlobeNewswire)
May-10-22 07:55AM	Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.70%
May-09-22 07:00AM	Trevena to Release First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
Apr-28-22 03:02PM	Analysts Estimate Trevena (TRVN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-20-22 07:00AM	Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects (GlobeNewswire)
Apr-18-22 07:00AM	Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund (GlobeNewswire) -7.42%
Apr-13-22 04:05PM	OLINVYK® data selected as Presidents Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting (GlobeNewswire)
Mar-31-22 11:26AM	Trevena shares skyrocket on $40 million royalty-based financing deal (American City Business Journals) +24.64%
08:15AM	Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:02AM	Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group (GlobeNewswire)
07:00AM	Trevena Reports Fourth Quarter and Full Year 2021 Results (GlobeNewswire)
Mar-30-22 07:00AM	Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022 (GlobeNewswire)
Mar-14-22 08:15AM	AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-07-22 06:55PM	Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-05-22 06:43AM	Is Trevena (NASDAQ:TRVN) In A Good Position To Invest In Growth? (Simply Wall St.)
Feb-03-22 07:00AM	Trevena to Present at the 2022 BIO CEO & Investor Conference (GlobeNewswire)
Jan-28-22 02:01PM	Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City (American City Business Journals)
Jan-27-22 09:00AM	Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical (GlobeNewswire) -5.40%
Jan-03-22 04:05PM	Trevena to Participate in the Upcoming January Conferences (GlobeNewswire) +6.97%
Dec-14-21 11:06AM	Trevena (TRVN) to Begin Clinical Study on Pain Candidate (Zacks)
Dec-13-21 07:00AM	Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain (GlobeNewswire)
Nov-15-21 12:25PM	Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -9.09%
07:00AM	Trevena Reports Third Quarter 2021 Results (GlobeNewswire)
Nov-11-21 07:00AM	Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team (GlobeNewswire)
Nov-08-21 07:00AM	Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021 (GlobeNewswire) -6.69%
Oct-25-21 03:01PM	Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline (Zacks)
Oct-13-21 07:00AM	Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021 (GlobeNewswire)
Oct-01-21 10:40AM	Is Trevena Stock a Buy Right Now? This Is What You Need to Know (TipRanks)
Sep-30-21 09:13AM	Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients (Benzinga)
07:00AM	Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients (GlobeNewswire)
Sep-17-21 07:00AM	Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) +11.48%
Sep-09-21 07:00AM	Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-30-21 07:00AM	Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021 (GlobeNewswire)
Aug-25-21 07:00AM	Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study (GlobeNewswire)
Aug-20-21 09:05AM	New Strong Sell Stocks for August 20th (Zacks)
Aug-12-21 09:55AM	Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.71%
07:00AM	Trevena Reports Second Quarter 2021 Results (GlobeNewswire)
Aug-10-21 07:00AM	Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy (GlobeNewswire)
Aug-09-21 07:00AM	Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021 (GlobeNewswire)
Jul-26-21 07:00AM	Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19 (GlobeNewswire) -5.44%
Jul-23-21 07:00AM	Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote For All Proposals Ahead of Special Meeting of Stockholders (GlobeNewswire) -5.77%

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRVN

Trevena Inc

Upgrade your FINVIZ experience